GEN Exclusives

More »

GEN News Highlights

More »
Mar 14, 2013

Lonza and Hyglos Reach Agreement Settling Patent Dispute

  • Lonza Walkersville and Hyglos signed an agreement that allows Hyglos to use recombinant factor C technology protected by Lonza’s patents to produce Hyglos’ own endotoxin products. The agreement also includes the dismissal of the lawsuit Lonza previously filed against Hyglos.

    “Thanks to this agreement an important door has opened for a new era in endotoxin detection. We are convinced that Hyglos’ innovative assays, entirely based on recombinant molecules, are addressing important needs of endotoxin testing laboratories worldwide” said Wolfgang Mutter, general manager of Hyglos.

    “We are very glad to have reached this agreement with Hyglos. Endotoxin detection using recombinant factor C instead of Limulus amoebocyte lysates has recently been acknowledged by the FDA as an alternative method. We believe that this sustainable animal-free alternative will be the future of endotoxin detection,” added Teun Van der Heide, Ph.D., head Lonza Bioscience.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?